Clinical Aspects of Vascular Dementia: From Bench to Bedside and Beyond
Özet
Vascular Dementia is the second most common cause of progressive and irreversible cognitive impairment worldwide. Cardiovascular risk factors, genetically determined forms of microangiopathies, neuroimaging core measurements, and serum biomarkers might be summarized as the four-cardinal area to unravel the cause. This specific review summarizes the occurrence of vascular dementia in the population, followed by the burden of vascular pathology in cognitive decline and the stroke-associated risk of dementia, and current VaD therapeutic treatments and future researches.
Referanslar
Wolters FJ, Ikram MA. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol.2019,39:1542-1549. (https://dx.doi.org/10.1161/ATVBAHA.119.311908)
O’Brien JT, Thomas A: Vascular dementia Lancet. 2015, 386:1698-706. (https://dx.doi. org/10.1016/S0140-6736(15)00463-8)
Power MC, Mormino E, Soldan A, James BD, Yu L, Armstrong NM, et al. Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol. 2018,84:10-22. (https://dx.doi.org/10.1002/ana.25246)
Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study Alzheimers Dement. 2018,14:280-292. (https://dx.doi. org/10.1016/j.jalz.2017.09.007)
Gorelick PB, Scuteri A, Black SE, et al. American Heart Association Stroke Council,Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/ american stroke association. Stroke. 2011, 42:2672-713. (https://dx.doi.org/10.1161/ STR.0b013e3182299496)
Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorder and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006, 37:2220-41. (https://dx.doi.org/10.1161/01. STR.0000237236.88823.47)
American Psychiatric Association: Diagnostic and statistical manual of mental disorders,Fifth Edition. American Psychiatric Publishing, Arlington, VA; 2013. (https:// doi.org/10.1176/appi.books.9780890425596.dsm17)
Kalaria RN, Maestre GE, Arizaga R, et al; World Federation of Neurology Dementia Research Group. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812–826. (https:// dx.doi.org/10.1016/S1474-4422(08)70169)
Jorm AF, Jolley D: The incidence of dementia: a meta-analysis. Neurology. 1998, 51:728- 33. (https://dx.doi.org/10.1212/wnl.51.3.728)
Kuźma E, Lourida I, Moore SF, et al. Stroke and dementia risk: A systematic review and meta-analysis. Alzheimers Dement. 2018, 14:1416-1426. (https://dx.doi.org/10.1016/j. jalz.2018.06.3061)
Allan LM, Rowan EN, Firbank MJ, Thomas AJ, Parry SW, Polvikoski TM, et al. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain. 2011;134(Pt 12):3716-27. (https://dx.doi.org/10.1093/brain/ awr273)
Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. 2009, 8:1006- (https:// dx.doi.org/10.1016/S1474-4422(09)70236-4)
Pendlebury ST, Rothwell PM; Oxford Vascular Study. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based oxford vascular study. Lancet Neurol. 2019;18:248–258. (https:// dx.doi.org/10.1016/S1474-4422(18)30442-3)
Munsch F, Sagnier S, Asselineau J, et al. Stroke location is an independent predictor of cognitive outcome. Stroke. 2016;47:66–73. (https://dx.doi.org/10.1161/ STROKEAHA.115.011242)
Tatemichi TK, Desmond DW, Prohovnik I, et al. Confusion and memory loss from capsular genu infarction: a thalamocortical disconnection syndrome? Neurology. 1992;42:1966–1979. (https://dx.doi.org/10.1212/wnl.42.10.1966)
Mok VC, Lam BY, Wong A, et al. Early-onset and delayed-onset poststroke dementia- revisiting the mechanisms. Nat Rev Neurol. 2017;13:148–159. (https://dx.doi. org/10.1038/nrneurol.2017.16)
Ballard, C, Rowan, E, Stephens, S, et al. Prospective follow-up study between 3 and 15 months after stroke: improvements and decline in cognitive function among dementia-free stroke survivors >75 years of age. Stroke 2003; 34:2440 4. (https://dx.doi. org/10.1161/01.STR.0000089923.29724.CE).
Looi JC, Sachdev PS. Differentiationofvasculardementiafrom ADonneuropsychological tests. Neurology 1999;53:670–8. (https://dx.doi.org/10.1212/wnl.53.4.670).
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699. (https://dx.doi.org/10.1016/0022-3956(75)90026-6)
Ylikoski R, Jokinen H, Andersen P, et al, and the LADIS Study Group. Comparison of the Alzheimer’s Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in diff erentiating elderly individuals with diff erent degrees of white matter changes. The LADIS Study. Dement Geriatr Cogn Disord 2007; 24: 73–81. (https://dx.doi.org/10.1159/000103865
Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards neuro-psychological battery after TIA and stroke. Stroke 2012;43:464–9. (https://dx.doi.org/10.1161/ STROKEAHA.111.633586).
Zietemann V, Georgakis MK, Dondaine T, et al. Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology. 2018 Nov 13;91(20):e1838-e1850. (https://dx.doi.org/10.1212/WNL.0000000000006506)
Gupta M, Dasgupta A, Khwaja GA, Chowdhury D, Patidar Y, Batra A. Behavioural and psychological symptoms in poststroke vascular cognitive impairment. Behav Neurol. 2014;2014:430128. doi: 10.1155/2014/430128. (https://dx.doi.org/ 10.1155/2014/430128)
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288: 1475–83. (https://dx.doi.org/10.1001/ jama.288.12.1475)
Kua EH, Ho E, Tan HH, Tsoi C, Thng C, Mahendran R. The natural history of dementia. Psychogeriatrics 2014; 14: 196–201. (https://dx.doi.org/10.1111/psyg.12053)
Skrobot OA, O’Brien J, Black S, et al. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2017 Jun;13(6):624-633. (https:// dx.doi.org/10.1016/j.jalz.2016.10.007)
Server Medical ART (https://smart.servier.com). (2021). Accessed: December 12: https:// smart.servier.com (https://smart.servier.com).
Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron 2017;96:17–42. (https://dx.doi.org/10.1016/j. neuron.2017.07.030).
Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, Dichgans M. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019 Jul 2;73(25):3326-3344. (https://dx.doi.org/10.1016/j.neuron.2017.07.030)
Zlokovic BV, Gottesman RF, Bernstein KE, et al. Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement. 2020 Dec;16(12):1714-1733. doi: 10.1002/alz.12157. (https:// dx.doi.org/10.1002/alz.12157)
Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev. 2010 Dec;68 Suppl 2(Suppl 2):S74-87. (https://dx.doi.org/10.1111/ j.1753-4887.2010.00352.x)
Lacolley P, Regnault V, Segers P, Laurent S. Vascular smooth muscle cells and arterial stiffening: relevance in development, aging, and disease. Physiol Rev 2017;97:1555–617. (https://dx.doi.org/10.1152/physrev.00003.2017)
Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 2019;25:270–6. (https://dx.doi. org/10.1038/s41591-018-0297-y)
Lulita MF, Noriega de la Colina A, Girouard H. Arterial stiffness, cognitive impairment and dementia: confounding factor or real risk? J Neurochem 2017;144:527–48. (https:// dx.doi.org/10.1111/jnc.14235)
Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844-66. (https:// dx.doi.org/10.1016/j.neuron.2013.10.008)
Vinters HV, Zarow C, Borys E, et al. Review: Vascular dementia: clinicopathologic and genetic considerations. Neuropathol Appl Neurobiol. 2018;44(3):247-266. (https:// dx.doi.org/10.1111/nan.12472)
Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M-G. CADASIL. Lancet Neurol 2009; 8: 643–53. (https://dx.doi.org/10.1016/S1474-4422(09)70127-9)
Tikka S, Baumann M, Siitonen M, et al. CADASIL and CARASIL. Brain Pathol 2014; 24: 524–44. (https://dx.doi.org/10.1111/bpa.12181)
Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49: 1322–30. (https://dx.doi.org/10.1212/ wnl.49.5.1322)
Kavanagh D, Spitzer D, Kothari PH, et al. New roles for the major human 3’-5’ exonuclease TREX1 in human disease. Cell Cycle 2008; 7: 1718–25. (https://dx.doi.org/10.4161/ cc.7.12.6162.)
Bugiani M, Kevelam SH, Bakels HS, et al. Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL). Neurology 2016; 87: 1777–86. (https://dx.doi. org/10.1212/WNL.0000000000003251).
Verbeek MM, deWaal RMW, Vinters HV (editors). Cerebral Amyloid Angiopathy in Alzheimer’s Disease and Related Disorders. Dordrecht/Boston: Kluwer Academic, 2000. (https://books.google.com.tr/books?hl= tr&lr= &id=R UQ4P FzDixwC&o i=f n d&pg=P R9&dq=C er e b ra l+A m y lo id+ Angiopathy+in+Alzheimer’s+Disease+and+Related+Disorders.+Dordrecht/ Boston:+Kluwer+Academic,+2000.&ots=wRXAYC6H40&sig=Ok1pQJYVKQR2 wdpGyoXz13vBa1A&redir_esc=y#v=onepage&q=Cerebral%20Amyloid%20 Angiopathy%20in%20Alzheimer’s%20Disease%20and%20Related%20Disorders.%20 Dordrecht%2FBoston%3A%20Kluwer%20Academic%2C%202000.&f=false).
Fein G, Di Sclafani V, Tanabe J, et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000; 55: 1626–35. (https://dx.doi. org/10.1212/wnl.55.11.1626)
Price CC, Jefferson AL, Merino JG, Heilman KM, Libon DJ. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Neurology 2005; 65: 376–82. (https://dx.doi.org/10.1212/01.wnl.0000168877.06011.15)
Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defi ned by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998; 55: 1217–25. (https://dx.doi. org/10.1001/archneur.55.9.1217)
de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70: 9–14. (https://dx.doi.org/10.1136/ jnnp.70.1.9)
Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, et al, and the LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009; 339: b2477. (https://dx.doi.org/10.1136/bmj.b2477)
Jagtap A, Gawande S, Sharma S. Biomarkers in vascular dementia: A recent update. Biomarkers and Genomic Medicine (2015); 7 (2): 43-56. (https://dx.doi.org/10.1016/j. bgm.2014.11.001)
Malaguarnera M, Ferri R, Bella R, Alagona G, Carnemolla A, Pennisi G. Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med. 2004;42(9):1032-5. (https://dx.doi.org/10.1515/CCLM.2004.208)
Tsimikas S, Hall JL. Lipoprotein(a) asapotentialcausalgeneticriskfactorofcardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60: 716e721. (https://dx.doi.org/10.1016/j. jacc.2012.04.038).
Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003;34(3):806-12. (https://dx.doi.org/10.1161/01.STR.0000058480.77236.B3)
Wallin A, Sjogren M. Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev. 2001;122:1937e1949. (https:// dx.doi.org/10.1016/s0047-6374(01)00306-2)
Sheinerman KS, Tsivinsky VG, Mullan MJ, Abdullah L, Umansky SR. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging. 2012;4:590e605. (https:// dx.doi.org/10.18632/aging.100486.)
Yamacuchi M. MicroRNAs in vascular biology. Int J Vasc Med. 2012:1e12. (https:// dx.doi.org/10.1155/2012/794898)
Satizabal C, Beiser AS, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016;375(1):93-4. (https://dx.doi.org/10.1056/ NEJMc1604823)
Malik R, Georgakis MK, Neitzel J, et al. Midlife vascular risk factors and risk of incident dementia: Longitudinal cohort and Mendelian randomization analyses in the UK Biobank. Alzheimers Dement. 2021;17(9):1422-1431. (https://dx.doi.org/10.1002/alz.12320)
Markus HS, Schmidt R. Genetics of vascular cognitive impairment. Stroke 2019;50:765– 72. (https://dx.doi.org/10.1161/STROKEAHA.118.020379)
Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390: 2673–734. (https:// dx.doi.org/10.1016/S0140-6736(17)31363-6)
Mogi M. Could Management of Blood Pressure Prevent Dementia in the elderly? Clin Hypertens. 2019;25:27. (https://dx.doi.org/10.1186/s40885-019-0135-7)
Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62:810–7. (https://dx.doi.org/10.1161/HYPERTENSIONAHA.113.01063)
Alateeq K, Walsh EI, Cherbuin N. Higher Blood Pressure is Associated with Greater White Matter Lesions and Brain Atrophy: A Systematic Review with Meta-Analysis. J Clin Med. 2021;10(4):637. (https://dx.doi.org/10.3390/jcm10040637)
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the RotterdamStudy. Neurology 1999;53:1937–1942. (https:// dx.doi.org/10.1212/wnl.53.9.1937)
Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537-547. 19 (https://dx.doi.org/10.1016/S2213-8587(16)30010-9)
Roberts RO, Knopman DS, Przybelski SA, et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology. 2014;82:1132-1141. (https://dx.doi. org/10.1212/WNL.0000000000000269)
Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292:2237-2242. (https://dx.doi.org/10.1001/ jama.292.18.2237)
Stern Y, Chételat G, Habeck C, et al. Mechanisms underlying resilience in ageing. Nat Rev Neurosci. 2019;20(4):246. (https://dx.doi.org/10.1038/s41583-019-0138-0)
Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta Neuropathol. 2016;131(5):659- 85. (https://dx.doi.org/10.1007/s00401-016-1571-z)
Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation. 2013;128(12):1341-8. (https://dx.doi.org/10.1161/CIRCULATIONAHA.113.002236)
Meschia JF, Bushnell C, Boden-Albala B, et al. ; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754-832. (https://dx.doi.org/10.1161/STR.0000000000000046)
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. (https://dx.doi.org/10.1161/CIR.0000000000000678)
Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016;1862(5):915-25. (https://dx.doi.org/10.1016/j. bbadis.2016.01.015)
Gottesman RF, Schneider AL, Albert M, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014;71:1218–27. (https://dx.doi.org/10.1001/jamaneurol.2014.1646)
Launer LJ, Hughes T, Yu B, et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu heart program/ Honolulu Asia aging study. Hypertension. 2010;55:1352–9. (https://dx.doi.org/10.1161/HYPERTENSIONAHA.109.147389)
Abell JG, Kivimaki M, Dugravot A, et al. Singh-Manoux a. association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J. 2018;39:3119–25. (https://dx.doi. org/10.1093/eurheartj/ehy288)
Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a doubleblind, placebo controlled trial. Lancet Neurol. 2008;7:683–9. (https://dx.doi. org/10.1016/S1474-4422(08)70143-1)
Peila R, Rodriguez BL, Launer LJ; Honolulu- Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;51:1256–1262. (https://dx.doi.org/10.2337/diabetes.51.4.1256)
Rawlings AM, Sharrett AR, Schneider AL, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 2014;161:785–793. (https://dx.doi. org/10.7326/M14-0737)
Punthakee Z, Miller ME, Launer LJ, et al.; ACCORD Group of Investigators; ACCORDMIND Investigators. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 2012;35:787–793. (https://dx.doi.org/10.2337/dc11-1855)
Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493. (https://dx.doi.org/10.2337/dci19-0066)
Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-64. (https://dx.doi.org/10.2337/dc12-1801)
Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ, et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep. 2018; 8(1): 5804. (https://dx.doi.org/10.1038/s41598-018-24248-8)
Poly TN, Islam MM, Walther BA,et al. Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies. Neuroepidemiology. 2020;54(3):214-226. (https://dx.doi.org/10.1159/000503105)
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467. (https://dx.doi.org/10.1161/STR.0000000000000375)
Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005;(2):CD003154. (https://dx.doi.org/10.1002/14651858.CD003154.pub3)
Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004;(1):CD004395. (https://dx.doi.org/10.1159/000088494)
Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005;20(6):338-44. (https://dx.doi.org/10.1159/000088494)
Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35. (https://www.dovepress.com/articles. php?article_id=178).
Amenta F, Lanari A, Mignini F, Silvestrelli G, Traini E, Tomassoni D. Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. J Neurol Sci. 2009;283(1- 2):219-23. (https://dx.doi.org/10.1016/j.jns.2009.02.335)
Kuang H, Zhou ZF, Zhu YG, et al. Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective. Aging Dis. 2021;12(1):308-326. (https://dx.doi. org/10.14336/AD.2020.0427)
